"ZEVASKYN represents a significant milestone for patients with RDEB and for the field of cell-based gene therapy," said Will Geist, Bio-Techne's President, Protein Sciences Segment. "We are honored ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback